The transforming growth factor (β1/interleukin-31 pathway is upregulated in patients with hepatitis B virus-related acute-on-chronic liver failure and is associated with disease severity and survival

Clinical and Vaccine Immunology

Volumn 22, Issue 5, 2015, Pages 484-492

  Yu, Xueping ^a   Guo, Ruyi ^a   Ming, Desong ^a   Deng, Yong ^b   Su, Milong ^a   Lin, Chengzu ^a   Li, Julan ^a   Lin, Zhenzhong ^a   Su, Zhijun ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

^b Pingxiang People's Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA FETOPROTEIN; BILIRUBIN; ENTECAVIR; GLUCOCORTICOID; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 31; INTERLEUKIN 33; INTERLEUKIN 35; INTERLEUKIN 9; LAMIVUDINE; TELBIVUDINE; TRANSFORMING GROWTH FACTOR BETA1; CYTOKINE; IL31 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

ACUTE ON CHRONIC LIVER FAILURE; ADULT; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CHILD PUGH SCORE; CHRONIC HEPATITIS B; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; EXPLORATORY RESEARCH; FEMALE; HEPATITIS B VIRUS; HUMAN; IMMUNOREGULATION; INTERLEUKIN 10 BLOOD LEVEL; INTERLEUKIN 17 BLOOD LEVEL; INTERLEUKIN 22 BLOOD LEVEL; INTERLEUKIN 23 BLOOD LEVEL; INTERLEUKIN 31 BLOOD LEVEL; INTERLEUKIN 33 BLOOD LEVEL; INTERLEUKIN 35 BLOOD LEVEL; INTERLEUKIN 9 BLOOD LEVEL; LIVER INJURY; MALE; MODEL FOR END STAGE LIVER DISEASE SCORE; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; SURVIVAL; TRANSFORMING GROWTH FACTOR BETA1 BLOOD LEVEL; UPREGULATION; BLOOD; END STAGE LIVER DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; LIVER; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; TIME FACTOR; VIROLOGY; YOUNG ADULT;

ACUTE-ON-CHRONIC LIVER FAILURE; ADULT; CYTOKINES; END STAGE LIVER DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS B, CHRONIC; HUMANS; INTERLEUKINS; LIVER; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA1; UP-REGULATION; YOUNG ADULT;

EID: 84929069258     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00649-14     Document Type: Article

References (33)

1. Perazella MA. 2009. Advanced kidney disease, gadolinium and nephrogenic systemic fibrosis: the perfect storm. Curr Opin Nephrol Hypertension 18:519-525. http://dx.doi.org/10.1097/MNH.0b013e3283309660.
2. Strain AJ, Frazer A, Hill DJ, Milner RD. 1987. Transforming growth factor beta inhibits DNA synthesis in hepatocytes isolated from normal and regenerating rat liver. Biochem Biophys Res Commun 145:436-442. http://dx.doi.org/10.1016/0006-291X (87) 91340-4.
3. Roberts AB, Sporn MB. 1993. Physiological actions and clinical applications of transforming growth factor-beta (TGF-beta). Growth Factors 8:1-9. http://dx.doi.org/10.3109/08977199309029129.
4. Miwa Y, Harrison PM, Farzaneh F, Langley PG, Williams R, Hughes RD. 1997. Plasma levels and hepatic mRNA expression of transforming growth factor-beta1 in patients with fulminant hepatic failure. J Hepatol 27:780-788. http://dx.doi.org/10.1016/S0168-8278 (97) 80313-3.
5. Yoshimoto N, Togo S, Kubota T, Kamimukai N, Saito S, Nagano Y, Endo I, Sekido H, Nagashima Y, Shimada H. 2005. Role of transforming growth factor-beta1 (TGF-beta1) in endotoxin-induced hepatic failure after extensive hepatectomy in rats. J Endotoxin Res 11:33-39. http://dx.doi.org/10.1179/096805105225006650.
6. Sonkoly E, Muller A, Lauerma AI, Pivarcsi A, Soto H, Kemeny L, Alenius H, Dieu-Nosjean MC, Meller S, Rieker J, Steinhoff M, Hoffmann TK, Ruzicka T, Zlotnik A, Homey B. 2006. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol 117:411-417. http://dx.doi.org/10.1016/j.jaci.2005.10.033.
7. Cornelissen C, Luscher-Firzlaff J, Baron JM, Luscher B. 2012. Signaling by IL-31 and functional consequences. Eur J Cell Biol 91:552-566. http://dx.doi.org/10.1016/j.ejcb.2011.07.006.
8. Knight D, Mutsaers SE, Prele CM. 2011. STAT3 in tissue fibrosis: is there a role in the lung? Pulm Pharmacol Ther 24:193-198. http://dx.doi.org/10.1016/j.pupt.2010.10.005.
9. Kato A, Fujii E, Watanabe T, Takashima Y, Matsushita H, Furuhashi T, Morita A. 2014. Distribution of IL-31 and its receptor expressing cells in skin of atopic dermatitis. J Dermatol Sci 74:229-235. http://dx.doi.org/10.1016/j.jdermsci.2014.02.009.
10. Neis MM, Peters B, Dreuw A, Wenzel J, Bieber T, Mauch C, Krieg T, Stanzel S, Heinrich PC, Merk HF, Bosio A, Baron JM, Hermanns HM. 2006. Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis. J Allergy Clin Immunol 118:930-937. http://dx.doi.org/10.1016/jjaci.2006.07.015.
11. Schulz F, Marenholz I, Folster-Holst R, Chen C, Sternjak A, Baumgrass R, Esparza-Gordillo J, Gruber C, Nickel R, Schreiber S, Stoll M, Kurek M, Ruschendorf F, Hubner N, Wahn U, Lee YA. 2007. A common haplotype of the IL-31 gene influencing gene expression is associated with nonatopic eczema. J Allergy Clin Immunol 120:1097-1102. http://dx.doi.org/10.1016/j.jaci.2007.07.065.
12. Raap U, Wieczorek D, Gehring M, Pauls I, Stander S, Kapp A, Wedi B. 2010. Increased levels of serum IL-31 in chronic spontaneous urticaria. Exp Dermatol 19:464-466. http://dx.doi.org/10.1111/j.1600-0625.2010.01067.x.
13. Ouyang H, Cheng J, Zheng Y, Du J. 2014. Role of IL-31 in regulation of Th2 cytokine levels in patients with nasal polyps. Eur Arch Oto-Rhino-Laryngo http://dx.doi.org/10.1007/s00405-014-2913-x.
14. Yu JI, Han WC, Yun KJ, Moon HB, Oh GJ, Chae SC. 2012. Identifying polymorphisms in IL-31 and their association with susceptibility to asthma. Korean J Pathol 46:162-168. http://dx.doi.org/10.4132/KoreanJPathol.2012.46.2.162.
15. Shiao YM, Chung HJ, Chen CC, Chiang KN, Chang YT, Lee DD, Lin MW, Tsai SF, Matsuura I. 2013. MCP-1 as an effector of IL-31 signaling in familial primary cutaneous amyloidosis. J Investig Dermatol 133:1375-1378. http://dx.doi.org/10.1038/jid.2012.484.
16. Bartram U, Speer CP. 2004. The role of transforming growth factor beta in lung development and disease. Chest 125:754-765. http://dx.doi.org/10.1378/chest.125.2.754.
17. Ge Q, Moir LM, Black JL, Oliver BG, Burgess JK. 2010. TGFbeta1 induces IL-6 and inhibits IL-8 release in human bronchial epithelial cells: the role of Smad2/3. J Cell Physiol 225:846-854. http://dx.doi.org/10.1002/jcp. 22295.
18. Shi K, Jiang J, Ma T, Xie J, Duan L, Chen R, Song P, Yu Z, Liu C, Zhu Q, Zheng J. 2014. Pathogenesis pathways of idiopathic pulmonary fibrosis in bleomycin-induced lung injury model in mice. Respir Physiol Neurobiol 190:113-117. http://dx.doi.org/10.1016/j.resp. 2013.09.011.
19. Xu L, Liu Q, Wang J. 2011. Dynamic changes and effects of interleukin-31 and transforming growth factor beta 1 in lung tissues of experimental mice with pulmonary fibrosi. J Heze Med Col 23:1-3. (In Chinese.)
20. Sun QF, Ding JG, Xu DZ, Chen YP, Hong L, Ye ZY, Zheng MH, Fu RQ, Wu JG, Du QW, Chen W, Wang XF, Sheng JF. 2009. Prediction of the prognosis of patients with acute-on-chronic hepatitis B liver failure using the model for end-stage liver disease scoring system and a novel logistic regression model. J Viral Hepat 16:464-470. http://dx.doi.org/10.1111/j.1365-2893.2008.01046.x.
21. Xu D, Fu J, Jin L, Zhang H, Zhou C, Zou Z, Zhao JM, Zhang B, Shi M, Ding X, Tang Z, Fu YX, Wang FS. 2006. Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol 177:739-747. http://dx.doi.org/10.4049/jimmunol.177.1.739.
22. Yu JW, Sun LJ, Zhao YH, Li SC. 2008. Prediction value of model for end-stage liver disease scoring system on prognosis in patients with acuteon-chronic hepatitis B liver failure after plasma exchange and lamivudine treatment. J Gastroenterol Hepatol 23:1242-1249. http://dx.doi.org/10.1111/j.1440-1746.2008.05484.x.
23. Zhang JY, Zhang Z, Lin F, Zou ZS, Xu RN, Jin L, Fu JL, Shi F, Shi M, Wang HF, Wang FS. 2010. Interleukin-17-producing CD4 (+) T cells increase with severity of liver damage in patients with chronic hepatitis B. Hepatology 51:81-91. http://dx.doi.org/10.1002/hep. 23273.
24. Zhang Z, Zou ZS, Fu JL, Cai L, Jin L, Liu YJ, Wang FS. 2008. Severe dendritic cell perturbation is actively involved in the pathogenesis of acute-on-chronic hepatitis B liver failure. J Hepatol 49:396-406. http://dx.doi.org/10.1016/j.jhep. 2008.05.017.
25. Zhai S, Zhang L, Dang S, Yu Y, Zhao Z, Zhao W, Liu L. 2011. The ratio of Th-17 to Treg cells is associated with survival of patients with acute-onchronic hepatitis B liver failure. Viral Immunol 24:303-310. http://dx.doi.org/10.1089/vim.2010.0135.
26. Ma WJ, Wang HY, Teng LS. 2013. Correlation analysis of preoperative serum alpha-fetoprotein (AFP) level and prognosis of hepatocellular carcinoma (HCC) after hepatectomy. World J Surg Oncol 11:212. http://dx.doi.org/10.1186/1477-7819-11-212.
27. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. 1973. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60:646-649. http://dx.doi.org/10.1002/bjs.1800600817.
28. Hu X, Ma S, Huang X, Jiang X, Zhu X, Gao H, Xu M, Sun J, Abbott WG, Hou J. 2011. Interleukin-21 is upregulated in hepatitis B-related acute-on-chronic liver failure and associated with severity of liver disease. J Viral Hepat 18:458-467. http://dx.doi.org/10.1111/j.1365-2893.2011.01475.x.
29. Zou Y, Chen T, Han M, Wang H, Yan W, Song G, Wu Z, Wang X, Zhu C, Luo X, Ning Q. 2010. Increased killing of liver NK cells by Fas/Fas ligand and NKG2D/NKG2D ligand contributes to hepatocyte necrosis in virus-induced liver failure. J Immunol 184:466-475. http://dx.doi.org/10.4049/jimmunol.0900687.
30. Zou Z, Li B, Xu D, Zhang Z, Zhao JM, Zhou G, Sun Y, Huang L, Fu J, Yang Y, Jin L, Zhang W, Zhao J, Sun Y, Xin S, Wang FS. 2009. Imbalanced intrahepatic cytokine expression of interferon-gamma, tumor necrosis factor-alpha, and interleukin-10 in patients with acute-on-chronic liver failure associated with hepatitis B virus infection. J Clin Gastroenterol 43:182-190. http://dx.doi.org/10.1097/MCG.0b013e3181624464.
31. Yu X, Guo R, Ming D, Su M, Lin C, Deng Y, Lin Z, Su Z. 2014. Ratios of regulatory T cells/T-helper 17 cells and transforming growth factorbeta1/interleukin-17 to be associated with the development of hepatitis B virus-associated liver cirrhosis. J Gastroenterol Hepatol 29:1065-1072. http://dx.doi.org/10.1111/jgh.12459.
32. Zhao J, Zhang Z, Luan Y, Zou Z, Sun Y, Li Y, Jin L, Zhou C, Fu J, Gao B, Fu Y, Wang FS. 2014. Pathological functions of interleukin-22 in chronic liver inflammation and fibrosis with hepatitis B virus infection by promoting T helper 17 cell recruitment. Hepatology 59:1331-1342. http://dx.doi.org/10.1002/hep. 26916.
33. Wang J, Cai Y, Ji H, Feng J, Ayana DA, Niu J, Jiang Y. 2012. Serum IL-33 levels are associated with liver damage in patients with chronic hepatitis B. J Interferon Cytokine Res 32:248-253. http://dx.doi.org/10.1089/jir.2011.0109.